To the Editor The article by Sarkar and colleagues1 recently published in JAMA Internal Medicine contributes to deeper knowledge of prostate cancer diagnosis in patients who are using 5-α reductase inhibitors (5-ARIs). As noted, the prediagnostic use of 5-ARIs is associated with delayed prostate cancer diagnosis, more advanced disease, and worse prostate cancer–specific and all-cause mortality compared with nonusers who underwent prostate-specific antigen (PSA) screening.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Medina CA, Zuluaga L, Plata M. 5α-Reductase Inhibitor Use in Patients With Prostate Cancer. JAMA Intern Med. 2019;179(10):1439. doi:10.1001/jamainternmed.2019.3623
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: